Vaccitech plc (NASDAQ:VACC – Get Free Report)’s share price shot up 7.2% on Wednesday . The company traded as high as $3.13 and last traded at $2.97. 33,918 shares changed hands during trading, a decline of 86% from the average session volume of 244,643 shares. The stock had previously closed at $2.77.
Analyst Ratings Changes
A number of research analysts recently commented on the stock. Alliance Global Partners started coverage on shares of Vaccitech in a report on Monday, September 25th. They issued a “buy” rating and a $12.00 price target for the company. Morgan Stanley lowered shares of Vaccitech from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $14.00 to $3.25 in a report on Monday, September 25th.
Vaccitech Price Performance
Institutional Investors Weigh In On Vaccitech
Several institutional investors and hedge funds have recently made changes to their positions in VACC. Baird Financial Group Inc. lifted its position in Vaccitech by 9.5% during the second quarter. Baird Financial Group Inc. now owns 196,296 shares of the company’s stock valued at $404,000 after purchasing an additional 17,000 shares during the period. Millennium Management LLC increased its stake in shares of Vaccitech by 32.8% during the fourth quarter. Millennium Management LLC now owns 40,388 shares of the company’s stock worth $97,000 after purchasing an additional 9,967 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Vaccitech by 198.2% during the second quarter. Renaissance Technologies LLC now owns 34,000 shares of the company’s stock worth $70,000 after purchasing an additional 22,600 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Vaccitech during the third quarter worth about $46,000. Finally, Citadel Advisors LLC purchased a new stake in Vaccitech during the 2nd quarter valued at about $31,000. 26.13% of the stock is currently owned by institutional investors and hedge funds.
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.
- Five stocks we like better than Vaccitech
- How to Invest in the Entertainment Industry
- 3 value stocks you shouldn’t let go of this quarter
- Find and Profitably Trade Stocks at 52-Week Lows
- 5 must-have next-gen technologies that institutions are buying
- Why Consider Investing in Nanotechnology Stocks
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.